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Abstract 
The polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene (BaP), was compared to 
dibenzo[def,p]chrysene (DBC) and combinations of three environmental PAH mixtures (coal tar, diesel 
particulate and cigarette smoke condensate) using a two stage, FVB/N  mouse  skin tumor model.  DBC 
(4 nmol) was most potent, reaching 100% tumor incidence with a shorter latency to tumor  formation,  
less than 20 weeks of 12-O-tetradecanoylphorbol-13-acetate (TPA) promotion compared to all other 
treatments. Multiplicity was 4 times greater than BaP (400 nmol).  Both PAHs produced primarily 
papillomas followed by squamous cell carcinoma and carcinoma in situ.  Diesel particulate extract (1 mg 
SRM 1650b; mix 1) did not differ from toluene controls and failed to elicit a carcinogenic response. 
Addition of coal tar extract (1 mg SRM 1597a; mix 2) produced a response similar to BaP.  Further 
addition of 2 mg of cigarette smoke condensate (mix 3) did not alter the response with mix 2. PAH-DNA 
adducts measured in epidermis 12 h post initiation and analyzed by 32P post- labeling, did not correlate 
with tumor incidence. PAH- dependent alteration in transcriptome of skin 12 h post initiation was 
assessed by microarray.  Principal component analysis (sum of all treatments) of the 922 significantly 
altered genes (p<0.05), showed DBC and BaP to cluster distinct from PAH mixtures and each other.  BaP 
and mixtures up-regulated phase 1 and 2 metabolizing enzymes while DBC did not.  The carcinogenicity 
with DBC and two of the mixtures was much greater than would be predicted based on published Relative 
Potency Factors (RPFs). 
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 Abbrevations: PAH-polycyclic aromatic hydrocarbon, BaP-benzo[a]pyrene, DBC-
dibenzo[def,p]chrysene, DPE-diesel particulate extract, CTE-coal tar extract, CSC-cigarette smoke 
condensate, RPF-relative potency factor, TBA-tumor bearing animal, BPDE-BaP-7,8-dihydrodiol-9,10 
epoxide, DBCDE-DBC-11,12-dihydrodiol-13,14 epoxide, AKR-aldo- keto reductase, ROS-reactive 
oxygen species, TPA-12-O-tetradecanoylphorbol-13-acetate, DRZ-diagonal radioactive zone, dG-N2-
BPDE-10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene, Nqo1-NAD(P)H-
quinone oxido reductase, Gst-glutathione-S-transferase, Gclc-gamma glutamylcysteine synthetase, CIS-
carcinoma in situ, SCC-squamous cell carcinoma 
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Introduction 
 
Polycyclic aromatic hydrocarbons (PAHs) are planar aromatic compounds with varying potencies of 
carcinogenicity defined by their individual structures (IARC, 2010).  PAHs occur naturally in the 
environment in fossil fuels such as coal, oil, and tar and are considered environmental pollutants formed 
during  incomplete combustion (coal, tobacco, diesel, asphalt, creosote, gasoline, wood smoke, etc.) 
leading to their presence in air, food and soils (Lijinsky, 1991; Weissenfels et al., 1992; Lewtas, 2007; 
Ding et al., 2011).  PAHs occur in the environment typically as mixtures covering a spectrum from non- 
toxic compounds to potent carcinogens (Baird et al., 2005; Mao et al., 2007; Allan et al., 2012; 
Wickramasinghe et al., 2012). Different types of combustion result in different compositions of PAHs 
both in relative amounts and individual PAHs present (Poster et al., 2000). Occupational exposure to 
PAH mixtures in aluminum production, iron and steel foundries, fossil fuel processing, wood 
impregnation, roofing and road sealing can pose risks for lung, skin, and bladder cancers (Boffetta et al., 
1997; IARC, 2010; Cogliano et al., 2011).  Epidemiological studies support a relationship between 
dermal exposure to PAHs and skin cancers (Boffetta et al., 1997; Marczynski et al., 2009; IARC, 2010). 
One of the most common cancers in Caucasian populations is non-melanoma skin cancer, recently 
reported to be on the rise throughout the world (Lomas et al., 2012). Benzo[a]pyrene (BaP), the most 
extensively studied carcinogenic PAH, is classified by IARC as a Group 1 or known human carcinogen 
(IARC, 2010).  Four of the top ten priority pollutants, designated by the Agency for Toxic Substances and 
Disease Registry (ATSDR) in 2011, are single PAHs or PAH mixtures (PAHs, BaP, 
benzo[b]fluoranthene, and dibenzo[a,h]anthracene) (ATSDR, 2011).  
 
 PAHs are carcinogenic in a number of animal models with multiple targets, including skin (Nesnow et 
al., 1998; Arif et al., 1999; Darwiche et al., 2007; Courter et al., 2008; IARC, 2010; Wester et al., 2011). 
Our laboratories have documented that dibenzo[def,p]chrysene (DBC), formerly referred to as 
dibenzo[a,l]pyrene,  is a potent carcinogen in mice (Marston et al., 2001; Yu et al., 2006; Mahadevan et 
al., 2007a; Castro et al., 2008a).  Oral administration results in tumors of the liver, lung, breast, ovaries 
and hematopoietic tissue. DBC can also be an effective transplacental carcinogen (Yu et al., 2006a; 
2006b;Castro et al., 2008a;  2008b; Guttenplan et al., 2011; Chen et al., 2012; Shorey et al., 2012).   
 
PAHs require bioactivation through metabolism in order to be mutagenic, carcinogenic or teratogenic to 
target cellular macromolecules (Baird and Mahadevan, 2004; IARC, 2010).  With higher molecular 
weight PAHs, such as BaP and DBC containing a “bay” and/or “fjord” region, respectively, the most well 
characterized bioactivation pathway has been cytochrome P450 (CYP)- dependent epoxygenation, 
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hydrolysis by epoxide hydrolase and a second CYP epoxygenation to the 7,8-dihydrodiol-9,10 epoxide 
(BPDE) in the case of BaP, and to the 11,12-dihydrodiol-13,14 epoxide (DBCDE) in the case of DBC 
(Shou et al., 1996; Xue and Warshawsky, 2005; Shimada, 2006). Hydrolysis of the initial epoxide 
produces two trans stereoisomers and the second epoxygenation can be above or below the plane of the 
ring; thus, four possible BPDEs or DBCDEs are produced. (Figure 1.) With BaP, the most mutagenic and 
carcinogenic BPDE is thought to be  (+)-7,8-anti-9,10-BPDE.  PAHs such as BaP and DBC can also be 
bioactivated through 1-electron oxidations (peroxidases) producing radical cations (Cavalieri and Rogan 
1992;1995) , predominantly at the 1,6- and 3,6-positions. Once formed these radical cations may bind to 
DNA. The role of aldo-keto reductases (AKRs) in bioactivation of PAHs has also been demonstrated 
(Penning et al., 1996; Palackal et al., 2001; 2002).  AKRs effectively convert the PAH dihydrodiol to a 
catechol.  As with other catechols, a redox-cycling can then occur through 1-electron reactions to the 
semi-quinone and quinone.  These reversible reactions generate superoxide anion radical and other 
reactive oxygen species (ROS) and can also directly react with nucleophilic sites on DNA.  The 
metabolism of PAHs through peroxidative and AKR-mediated pathways is consistent with oxidative 
stress- associated PAH toxicity (Kumar et al., 2012).   
 
The most important CYPs in PAH metabolism are CYP1A1, CYP1A2, CYP1B1, and to a lesser extent 
CYP2C9 and CYP3A4 (Shimada, 2006).  Recent evidence from our laboratories and others has suggested 
that CYP1B1 plays a predominant role in the toxicity and carcinogenicity of both BaP and DBC in the 
mouse (Uno et al., 2006; Castro et al., 2008a).  
 
The murine two-stage skin tumor model has been used extensively to investigate mechanisms of 
carcinogenesis (Cavalieri et al., 1991; Higginbotham et al., 1993) and the inbred FVB strain has been 
shown to be suitable for initiation/promotion studies (Hennings et al., 1993). This model is a powerful 
tool for studying early indicators of “high risk” papillomas that can develop into invasive squamous cell 
carcinomas (Glick et al., 2007). The vast majority of cancer studies in animal models have tested single 
PAHs. Unfortunately this is incongruous with the complex mixtures of PAHs to which human 
populations are exposed. In this study we sought to examine the relative potency of BaP and DBC, 
compared to combinations of some environmentally relevant PAH mixtures. We hypothesized that early 
PAH-dependent alterations in the transcriptome of mouse epidermis following initiation could be 
correlated with DNA adduct formation at the same time point and predict probable tumor outcomes.  The 
EPA is currently evaluating the potential of a Relative Potency Factor (RPF) approach in estimating risk 
for exposure to PAH mixtures.  Our results demonstrate that, at least with respect to skin cancer following 
dermal exposures, the RPF markedly underestimates DBC and PAH mixture potency.  Furthermore, 
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alterations in gene expression 12 h post-initiation suggest the strong possibility that these PAH treatments 
are acting through multiple and distinct mechanisms. 
 
Materials and methods 
Caution: BaP and DBC are potent carcinogens and should be handled in accordance with National Cancer 
Institute (NCI) guidelines. All pure PAHs and mixtures were prepared under UV depleted light. 
 
Chemicals.  BaP and DBC were purchased from Midwest Research Institute ( Kansas City MO). Diesel 
particulate (SRM 1650b), and coal tar extract (CTE, SRM 1597a)  were purchased from the National 
Institute of Standards & Technology, Gaithersburg, MD. Cigarette smoke condensate (CSC) was a gift 
from Dr. Hollie Swanson, University of Kentucky. RNases, proteinase K, and Trizol® were purchased 
from Life Technologies™ (Invitrogen, Grand Island, N.Y). Dichloromethane, toluene, acetone, and 
DMSO were obtained from Fisher Scientific (Pittsburgh, PA). All other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
Preparation of PAH mixtures.  Diesel particulate, SRM 1650b, (200 mg) was placed in a 25 x 80 mm 
thimble, Schleicher & Schull # 350217 (Keene, N.H.) and extracted with 200 ml dichloromethane in a 
Soxhlet apparatus at 40° C for 24 h. The final extract was concentrated and exchanged into toluene, and 
evaporated with N2 gas to a final volume of 10 ml. An aliquot was diluted with toluene containing 5% 
DMSO to make PAH mix 1 equivalent to 5 mg/ml diesel particulate extract (DPE). CTE SRM 1597a, was 
concentrated to 10 mg/ml by evaporating with a stream of N2 gas. PAH mix 2 (DPE+CTE) contained 5 
mg/ml DPE and 5 mg/ml CTE. CSC was received as a 40 mg/ml stock solution in DMSO. In order to 
keep the final DMSO concentration at or below 5%, CSC was evaporated in a Savant Speed Vac 
centrifuge to 200 mg/ml and was diluted to 40 mg/ml with toluene. PAH mix 3 was comprised of mix 2 
plus 10 mg/ml cigarette smoke condensate (DPE +CTE + CSC). 
 
Skin tumor study.  All procedures were conducted according to National Institutes of Health guidelines 
and were approved by the Oregon State University Institutional Animal Care and Use Committee. Six- 
week-old, female FVB/N inbred mice were obtained from the NCI-Fredrick’s Animal Production 
Program (Frederick, MD). Most of the historical skin tumor data from our laboratory has been done with 
the Sencar mouse. The FVB/N strain was chosen because an inbred strain is more suitable for  gene 
profiling, it has been proven to give a robust tumor response to chemically initiated carcinogenesis and 
could be readily backcrossed into specific knockout or transgenic mouse models for future studies. Mice 
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were acclimated for ten days and fed AIN93-G pellets, Research Diets, Inc. (New Brunswick, N.J.) 
throughout the experiment. Animals were housed in micro-ventilated racks, four animals per cage on a 
standard 12 h light/dark cycle, at 22°C and 40-60% humidity.  At 7.5 weeks of age, mice were shaved on 
their dorsal surface and allowed to rest 48 h to confirm that animals were in the resting phase of the hair 
growth cycle. The following initiation treatments were applied to groups of 36 mice by slowly pipetting 
solutions on the shaved area; toluene vehicle control (200 µl), BaP 400 nmol (100 µg), DBC 4 nmol (1.2 
µg), DPE 1 mg (mix 1), DPE 1 mg + CTE 1 mg (mix 2), or DPE 1 mg + CTE 1 mg + CSC 2 mg (mix 3). 
In order to handle the large sample sizes, mice were shaved and initiated in three different cohorts 
separated by a one week start time.  Multiple animals for all treatments were included within each cohort.  
Two weeks post-initiation, a 25-week promotion regimen was begun, treating animals twice weekly with 
12-O-tetradecanoylphorbol-13-acetate (TPA), 6.5 nmol in 200 µl acetone. Mice were observed and tumor 
incidence recorded weekly throughout the 25-week promotion interval. Following promotion, all animals 
were euthanized and necropsied. Skin tumors were removed and immediately fixed in buffered formalin. 
Trimmed tumors were embedded in paraffin.  Haematoxylin and eosin-stained sections were analyzed by 
histopathology to determine degree of progression from papilloma to squamous cell carcinoma.  
 
DNA extraction from PAH-treated epidermis.  For measurement of DNA adduct levels, groups of 10 mice 
were treated with initiators as above and euthanized 12 h post-treatment by a combination of CO2 and 
cervical dislocation. Epidermal cells were harvested using the method of (Slaga et al., 1974). Shaved 
dorsal skin was removed and treated with Nair™ depilatory cream (Church & Dwight Inc., Princeton, 
N.J.) for 8 min to remove hair from follicles. Skin was wiped with sterile water and submerged in a 58°C 
water bath for 30 s then submerged in an ice water bath to loosen the epidermal layer. Epidermal cells 
were scraped away from the dermis with a razor blade and snap frozen in liquid N2. Samples from two 
mice were pooled and homogenized in 0.5 ml buffer (5 mM Tris, 5 mM EDTA,100 mM NaCl, 2 mM 
CaCl2, 1% (w/v) SDS, pH 8.0) using a Tissue Tearor™ (BioSpec Products, Inc. Bartlesville, OK). 
Homogenates were treated with 10 µl RNase, (DNase free 50 U/ml) and 10 µl RNase T1 (1000 U/ml) and 
incubated at 37°C for 1 h followed by addition of 20 µl of proteinase K (20 mg/ml) and incubated at 55° 
C for 2 h. DNA was extracted with 25:24:1 phenol:chloroform:isoamyl alcohol, precipitated with 100% 
ethanol, washed with 75% ethanol, and dissolved in DNase-free water. 
 
DNA adducts analysis by 32P-postlabeling.  DNA adduct formation was measured for each sample using 
the nuclease P1 enrichment version of the 32P-postlabeling method as described previously (Phillips and 
Arlt, 2007; Arlt et al., 2008). Briefly, DNA samples (4 µg) were digested with micrococcal nuclease (120 
mU, Sigma, UK) and calf spleen phosphodiesterase (40 mU, Calbiochem, UK), enriched and labelled as 
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reported. Solvent conditions for the resolution of 32P-labelled adducts on polyethyleneimine-cellulose 
thin-layer chromatography (TLC; Macherey-Nagel, Düren, Germany) were: D1, 1.0 M sodium phosphate, 
pH 6.0; D3, 4 M lithium-formate, 7 M urea, pH 3.5; D4, 0.8 M lithium chloride, 0.5 M Tris, 8.5 M urea, 
pH 8.0. DNA adduct levels were calculated from the adduct dpm, the specific activity of [γ-32P]ATP 
(Hartmann-Analytic, Braunschweig, Germany) and the amount of DNA (pmol of DNA) used. As in prior 
studies, total DNA adduct levels were measured in the diagonal radioactive zone (DRZ) area of the TLC 
plates and were considered representative of PAH-DNA and other aromatic/hydrophobic adducts resistant 
to nuclease P1 digestion (Tang et al., 2001). The method provides a summary measure of a complex 
mixture of adducts present in the postlabeling chromatograms. Results were expressed as DNA 
adducts/108 nucleotides. An external BPDE-DNA standard was employed for identification of adducts in 
experimental samples (Phillips and Castegnaro, 1999). 
 
RNA extraction from PAH-treated skin.  Five mice per treatment group were given one initiation dose 
using the same techniques and treatments as described in the tumor study. Shaved skin was harvested 12 
h after treatment and RNA extracted for gene expression analysis. In order to eliminate RNase 
degradation, epidermis and dermis layers were kept intact, removed as one piece and snap frozen in liquid 
nitrogen. A 1-cm2 section of frozen skin was placed in a 15-ml sterile, disposable conical homogenizer, 
VWR Scientific Inc. (San Francisco, CA.) and homogenized in 2 ml Trizol® reagent. RNA was extracted 
according to the manufacturer’s instructions followed by a clean-up step using an RNeasy® mini kit, 
Qiagen Corp. (Valencia, CA.). RNA was quantitated on a Nanodrop spectrophotometer, Thermo 
Scientific (Wilmington, DE.). Acceptable A260/A280 ratios were 1.9-2.2. Sample quality was confirmed by 
examining18S and 28S peaks using an Agilent Technologies Bioanalyzer 2100 (Santa Clara, CA.); RNA 
samples with relative integrity numbers of 6.5 or greater were used in array analysis. 
 
Gene profiling with Agilent microarrays.  The RNA was labeled with Agilent’s 2 color Quickamp kit and 
the platform utilized was the Agilent 8X60 K mouse array. 
 
Statistical analysis.  Time to first tumor was initially compared across the six treatments using the 
Wilcoxon and Log-rank tests followed by pairwise comparisons (with Tukey adjustment) in the SAS 
Lifetest procedure  version 9.3, SAS Institute, Cary, NC.  For  the 4 treatments with greater than 10% 
incidence a more complex and conservative shared frailty model was also fit due to evidence of 
differences in treatment effects across the cohorts in the study.  The model was fit with the SAS Phreg 
(Proportional Hazards regression) procedure with the random clusters being the treatment groups within 
each cohort.  Because all treatment differences are either very large or very small, the conclusions did not 
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change using the more complex model and only the simpler initial tests results are shown.  The four 
treatments (BAP, DBC, Mix 2 and Mix3) with more than 1 tumor-bearing animal (TBA) were compared 
with respect to their tumor multiplicity per TBA.  The exact Kruskal-Wallis (K-W) rank test (SAS 
npar1way procedure) was used to compare multiplicity for three of the treatments (BAP, Mix 2 and Mix 
3) because no evidence was found of cage or cohort differences within those treatments (p>0.3 all 3 K-W 
tests).  DBC multiplicity was compared to the other three treatments with more conservative tests due to 
evidence of cage differences within that treatment (p<0.005 K-W test).  The more conservative and 
approximate model was a linear mixed model with log of multiplicity as the response and heterogeneous 
random cage effects that are allowed to be different for the DBC treated group (SAS Mixed procedure).  
 
Quality control analysis was performed on preprocessed data in GeneSpring v.11 (Silicon Genetics) 
software using feature intensity distributions from Box-whisker plots to determine interquartile range 
span and median intensity value across the experiment. The intra-group versus between-group 
comparisons were made using correlation matrix plots, followed with principle components analysis to 
determine potential outliers. Raw Agilent intensity data were background subtracted and quantile-
normalized by RMA summarization as described by (Bolstad et al., 2003). Statistical analysis was 
performed by one-way ANOVA for unequal variances (Welch’s ANOVA) with Tukey’s posthoc test and 
5% FDR.  Unsupervised bidirectional hierarchical clustering of microarray data were performed using 
Euclidean distance metric and centroid linkage clustering to group treatments and gene expression 
patterns by similarity.  Principal components analysis was performed on condition using non-transformed 
normalized intensity values.  The clustering algorithms, heat map visualizations and centroid calculations 
were performed in GeneSpring software based on log2 expression ratio values.  Functional analysis was 
performed in Bioinformatics Resource Manager v2.3 (Shah et al., 2007)  using the DAVID functional 
annotation tool (Huang da et al., 2009), which utilizes the Fisher Exact test to measure gene enrichment in 
biological process Gene Ontology (GO) category terms for significant genes compared to background, 
which included all genes on the Agilent platform.   
 
Results 
Time to tumor, multiplicity, and progression 
 
Toluene control and diesel extract (mix 1) treatment groups were similar in time to tumor (p>0.5). These 
two treatments were also very different from the other treatments (p<0.0001 for all pairwise 
comparisons). BaP and the remaining two mixtures, DPE + CTE (mix 2), and DPE + CTE+ CSC (mix 3), 
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had similar outcomes to one another for time until tumor event (p>0.5 all 3 pairwise comparisons) and 
were different from controls (p<0.001), DPE (p<0.001) and DBC (p<0.001) (Figure 2). Control and mix 1 
produced only one papilloma in the entire group (3% incidence) by the end of twenty weeks of promotion 
and therefore were not used in statistical modeling of tumor multiplicity.  BaP, mix 2 and mix 3, were 
also similar in tumor multiplicity with 2.88 ± 2.33, 2.03 ± 1.42, and 2.21 ± 1.14 tumors per tumor-bearing 
animal, respectively (Figure 3). DBC was different from all the other treatments with respect to time to 
tumor formation (p<0.001, Figure 2) and multiplicity, 7.88 ± 3.48 tumors per tumor-bearing mouse 
(Figure 3).  Tumor progression was assessed from initial hyperplasia and classified as dysplasia, 
papilloma, carcinoma in situ, or squamous cell carcinomas (Figures 4 and 5). With only one papilloma, 
DPE application to the skin did not elicit a carcinogenic response. The overall trend was again seen with 
respect to a similarity between BaP (32 mice), mix 2 (34 mice) and mix 3 (33 mice) with hyperplasia in 
14, 14, and 12 animals; papillomas in 25, 25, and 27 animals; and carcinoma in situ in 8, 2, and 6, 
animals, respectively. BaP treatment resulted in a slightly higher incidence of squamous cell carcinomas 
(17) compared to mix 2 and mix 3 (10 and 7, respectively). DBC was far more potent, producing 37 total 
hyperplasias and 125 papillomas.  Although the total number of all tumor types was greater with DBC, 
the rate of progression from papilloma to carcinoma in situ and squamous cell carcinoma showed similar 
ratios as BaP , 28 cases of carcinoma in situ and 75 squamous cell carcinomas. 
 
  
DNA adduct formation in mouse skin 
 
DNA adducts were quantified at 12 h in skin of the mouse following one initiation treatment with BaP, 
DBC, or a PAH mixture. Adducts migrating across the diagonal radioactive zone (DRZ) of the TLC 
image were compared and expressed as total adducts (Figure 6). BaP had over three times the level of 
total DNA adducts compared to DBC (141 ± 37 versus 45 ± 13 adducts/108 nucleotides, Figure 6A).  As 
shown in Figure 6B the TLC autoradiogram for the BaP-treated mouse skin DNA showed one major  
spot; this adduct was identified as reported previously (Arlt et al, 2008) as 10-(deoxyguanosin-N2yl)-
7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE)  that co-migrated with the  (±)-7,8-
anti-9,10-BPDE-DNA standard . DBC produced a less intense spot with a similar mobility to the BPDE-
DNA standard plus two additional spots; one major, faster migrating and a minor slower one. Our 
laboratory has seen a similar pattern when comparing B[a]P and DBC 32P-post labeled adducts at 24 h 
post initiation in Sencar mice ( Courter et al. 2008). Buters et al.( 2002) showed embryonic fibroblasts 
from wild type mice produced three major and two minor adduct peaks 24h after treatment with 100nM 
DBC.  Four of the peaks formed from (-)-anti-DBCDE and two peaks from (+)-syn-DBC.. All three PAH 
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mixes produced only one spot on the TLC autoradiogram similar to the location of the  (±)-7,8-anti-9,10-
BPDE-DNA standard.  DNA adduction formation  as determined by 32P post-labeling, 12 h following 
PAH administration, did not predict the relative tumor potency of BaP, DBC or the PAH mixtures.  
 
Gene expression in mouse skin 
 
Global gene analysis using Agilent microarrays resulted in a total of 922 genes expressed at significant 
levels (p<0.05, 5% FDR) across all treatment groups compared to toluene controls.  Raw and normalized 
Agilent data files are available online at http://www.ncbi.nlm.nih.gov/geo/query/.   Principal 
components analysis of the 922 significant genes showed strong separation of the data based on PAH 
exposure with biological replicates clustering by treatment group (Figure 7). Mix 2 and 3, which both 
contained diesel exhaust and coal tar extract, had overlapping clusters indicating similarity in gene 
expression between these groups.  Mix 1, which included the diesel exhaust, did not cluster with the coal 
tar mixtures, indicating the gene expression changes in mix 2 and 3 were driven by the coal tar extract.  
Instead, mix 1 clustered closely with the toluene control group consistent with its lack of potency and also 
had the fewest number of differentially regulated genes relative to the other treatments.  In comparison, 
the BaP and DBC clusters were distinct from each other and from all the mixtures. The certified 
concentration of B[a]P in CTE (NIST SRM 1597a) used in mix 2 and 3 was 93.5 ± 1.4 mg/kg. We 
applied 1 mg CTE which translated to 0.094 µg/animal, about 0.1% of the BaP treatment, and an RPF of 
0.34 BaPeq compared to 100 for the B[a]P treatment. This suggests there were additional components in 
the CTE driving the carcinogenic alterations in mouse skin transcriptome resulting in a similar tumor 
response in BaP, mix 2 and 3 . 
 
The results indicated that the coal tar extract was likely driving the carcinogenic potential and the 
transcriptional response of the PAH mixtures.  In order to look more closely at gene transcription by coal 
tar extract, the three PAH mixture treatments were directly compared to each other to identify genes 
regulated in common between mixtures 2 and 3, but unique from mixture 1.  A Venn diagram comparing 
the alteration in gene expression in the skin, 12 h after application of the PAH mixtures, demonstrated 
that there were 234 genes in common when comparing mix 2 and 3 to toluene controls (Figure 8A).  
Visualization of these genes in a heatmap confirms that they are regulated in common (based on direction 
and magnitude) between mix 2 and 3, but were not regulated by mix 1 (Figure 8B).  Since these genes in 
particular may provide insight into mechanisms associated with induction of skin tumorigenesis, the 
biological processes significantly (p<0.05) enriched for this gene set were identified.  The major gene 
pathways up-regulated were associated with xenobiotic metabolic response, carbohydrate biosynthesis 
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and hemopoiesis, whereas down-regulated pathways included  genes associated with DNA repair, 
microtubule cytoskeleton organization, mitotic sister chromatid exchange, M phase of the cell cycle and 
nucleosome assembly (Figure 8B). 
 
Many of the genes up-regulated by mix 2 and 3 and associated with xenobiotic metabolic response were 
also significantly up-regulated (p<0.05) by BaP treatment, including strong induction (4-fold change or 
greater) of Cyp1a1 and Cyp1b1 (Figure 9).  Consistent with its lack of potency in producing skin tumors 
after 25 weeks promotion, the diesel particulate extract (mix 1) had only a modest impact on CYP enzyme 
expression.  Interestingly, an initiation dose of DBC did not induce expression of either gene and, in fact, 
resulted in a trend towards down regulation of Cyp1a1 and Cyp1b1 that did not reach statistical 
significance. With respect to phase 2 enzymes, which are expected to contribute to the detoxication of 
DBC, a similar pattern was again seen across the PAH treatment groups (Figure 9). Up-regulation was 
fairly robust by BaP, mix 2 and 3 for NAD(P)H-quinone oxidoreductase 1 (Nqo1), glutathione-S-
transferases Gsta1, and Gsta2 as well as gamma glutamylcysteine synthetase (Gclc).  Alteration in 
expression of Gstp1, Gstp2 and Gstm5 was much more modest and, in fact, expression of the latter Gsts 
was less with BaP than seen with mix 2 or mix 3 (Figure 9). DBC again gave quite different results with 
modest decreases or no change in expression of these phase 2 enzymes. 
 
Discussion 
The mouse skin initiation-promotion model has been used extensively to assess the carcinogenicity of 
numerous PAHs, singularly and as mixtures  (IARC, 2010) (LaVoie et al., 1993).  The EPA and other 
agencies use this data, along with results from other animal models, to assess the RPF for PAHs.  In this 
study we employed female FVB/N mice to compare the potency of some complex PAH mixtures found in 
the environment to the characterized skin carcinogens BaP and DBC. Given the marked increase in tumor 
incidence, multiplicity and time-to-tumor formation with DBC at 1/100 the molar dose of BaP, we assert 
that the  potency of DBC in this two-stage skin tumor model was more than 100-fold greater than that of 
BaP and is inconsistent with the current EPA estimate of a BaPeq of 30 for DBC. (Figures 2and 3).  At 
100 µg, the RPF of BaP was 100 and DBC 36 µg BaPeq (1.2 µg x 30). The yield of squamous cell 
carcinomas was also greater with the 1/100-fold lower DBC dose than with BaP (Figure 4). Thus, the 
RPF of DBC in this model is much greater than the currently proposed value of 30 (BaP set at 1).  To 
determine a more accurate RPF for DBC in this model, we would need to conduct a dose-response study.  
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Examining the results with the environmental PAH mixtures, a similar underestimation of potency can be 
seen.  Based on the published RPFs for the PAHs in the coal tar extract (SRM 1597), the RPF for mix 2 
would be 0.34 µg BaPeq and one would predict a much weaker tumor response compared to BaP alone; 
however the incidence, latency, multiplicity and tumor type were no different.  It is entirely possible that 
DBC and the mixtures exhibit greater promotional activity than BaP (i.e., are more complete 
carcinogens).  Certainly, with the mixture extracts, there are other components that could be capable of 
enhancing the TPA promotional activity.  These results were somewhat unexpected given previous 
demonstration that this same PAH mixture inhibits the metabolic activation of BaP and DBC in MCF-7 
cells (Mahadevan et al., 2005) and V79 cells expressing either CYP1A1 or CYP1B1 (Mahadevan et al., 
2007b).  The experimental design employed was novel in that we wanted to assess the effect of “mixtures 
of mixtures”.  The lack of response with diesel extract is consistent with the low RPF of 0.004 µg BaPeq.  
It would also appear that the increase in RPF (0.47µg, or 0.13 µg above mix 2) with the addition of CSC 
did not affect carcinogenicity.  It is apparent though that the current RPF system for estimation of 
carcinogenic potency of environmental PAH mixtures or even individual PAHs such as DBC, is 
inadequate.  Our previous observations have shown that individual PAHs exhibit less than additivity and 
can compete with more potent individual PAHs for the same enzymes (Courter et al., 2006; 2008, 
Mahadevan et al., 2007a) It is also  unlikely that complex environmental PAH mixtures have been 
exhaustively characterized with respect to all components and accurate RPFs determined. It would seem a 
more prudent approach when conducting risk assessments to utilize RPFs of mixtures rather than a 
summation of individual PAHs.  It would also seem prudent to more thoroughly test PAHs such as DBC 
that exhibit high carcinogenic potency (levels of DBC are rarely reported in environmental samples) using 
additional models (both in vivo animal models and in vitro human cell models).  The distinct pattern of 
gene expression with DBC also raises an important question with respect to whether or not all PAHs are 
carcinogenic through the same mechanism of action (MOA) which is important with respect to whether or 
not an RPF approach for carcinogenic risk assessment for mixtures is appropriate. 
  
Another conclusion from this study is that PAH-DNA adduct formation in skin after single administration 
did not predict the final tumor response (Figure 6).  Based on the total DNA adducts present in skin 12 
hours post-initiation, one would predict that BaP would give the most robust tumor response (3-fold 
greater than DBC). Measuring adducts at one time point may not be sufficient for comparing these 
particular PAHs; however (Courter et al. 2008) found similar results at 24 h in Sencar mice. An attempt 
was made to investigate a time when adduct formation would be at peak levels. The 12 h post initiation 
time was chosen for measuring DNA adduct formation based on previous work in our lab (Marston et al., 
2001). Sencar mice treated topically with BaP showed peak DNA adduct levels at 12 h. Adduct levels in 
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DBC treated animals peaked at 12 h and  were sustained until 24 h post treatment.  It has been well 
documented that PAH structural features (Geacintov et al. 2002, Wu et al., 2002),  specific types of 
adducts formed (Dreij et al., 2005), DNA repair enzyme recognition (Braithwaite et al., 1999), and 
replication bypass fidelity (Lagergvist et al., 2011) all contribute to levels of PAH caused  mutagenicity. 
BaP forms predominantly adducts at the N2 position of dG while DBC forms more at the N6 position of 
dA . The bay region containing BaP is a planar , less flexible molecule compared to the fjord containing 
DBC.  These two structural features in DNA adduct formation are thought to enable DBC adducts to sit in 
the large groove of the helix and be unrecognized by repair enzymes (Geacintov et al., 2002). Initial DNA 
damage, persistence of the damage, as well as the mutagenic specificity of individual DNA adducts, all 
contribute to the mutagenic potency and subsequently carcinogenic potency of the tested PAHs. This 
suggests that one must be cautious in interpretation of DNA adduction as a biomarker of PAH dependent 
skin tumorigenesis, especially if relying on a single time point or comparing PAHs that may be 
bioactivated through a variety of pathways.  
 
In order to determine similarities and differences in comparing DBC, BaP and the PAH mixtures with 
respect to potential mechanisms of action, we examined alterations in the transcriptome of the skin 12 h 
post-initiation.  A total of 922 genes were significantly up or down regulated cumulatively for all 
treatment groups relative to the toluene control.  PAHs are known to exert toxicity, including 
carcinogenesis, through alteration of Ahr-regulated genes (Andrysik et al., 2011).  As expected BaP and 
the mixtures containing coal tar extract significantly induced both Cyp1a1 and Cyp1b1.  The response 
with DBC was unexpected.  Although DBC is a much more potent skin carcinogen, dermal Cyp1a1 and 
Cyp1b1 expression was not induced but was slightly decreased (Figure 9).  PAHs are also known to 
exhibit toxicity through induction of oxidative stress (Kumar et al., 2012).  A number of genes regulated 
by the Keap 1- Nrf-2 signaling system (Niestroy et al., 2011) were up-regulated by BaP and the coal tar-
containing mixtures but, again, DBC had no effect or slightly down-regulated expression (Figure 9).  
Principal component analysis confirmed that DBC altered a set of genes that did not cluster with BaP or 
the coal tar-containing mixtures (Figure 7).  In support of the enzyme expression profiles and clustering 
analysis, we observed that the biological process, response to xenobiotic stimulus (GO:0009410), was 
significantly (p<0.05) enriched by BaP and not by DBC.  In fact, the genes in this category were strongly 
up-regulated by BaP and either not changed or slightly down-regulated by DBC at 12 hours post-
initiation.  These data suggest that BAP may be inducing a protective response early during initiation 
through up-regulation of xenobiotic metabolism, while DBC exposure may result in a less protected 
cellular environment resulting in a higher tumor incidence.  Future studies will examine the regulatory 
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differences between BaP and DBC to understand how early changes during initiation may contribute to 
tumor outcome.      
 
The principal components analysis also revealed that the coal tar mixtures clustered separately from both 
DBC and BaP (Figure 7).Our study shows that the coal tar extract is driving both the tumor incidence and 
gene expression profiles of the environmental PAH mixtures.  Therefore, we focused our bioinformatic 
analysis of the transcriptional data on genes that are expressed in common between mixtures 2 and 3, but 
unique from mixture 1, to identify mechanisms associated with skin tumorigenesis. The Venn diagram 
(Figure 8A) shows that over 50% of the genes altered by mix 2 or 3 (270 out of 428 or 521, respectively) 
were shared between them and only a fraction of these genes (13% or 36 out of 270) were also shared 
with mix 1.  These results call into question whether or not PAHs, in such environmental mixtures, share 
a common mode of action (MOA), an assumption important in utilizing an RPF approach in risk 
assessment.  Functional analysis of the genes specific to the coal tar PAH mixtures (Figure 8B) suggest 
that down-regulation of  DNA repair and cell cycle processes and up-regulation of xenobiotic metabolism 
are consistent with the enhanced tumorigenicity of these mixtures compared to diesel extract. 
 
In conclusion, the results from this study suggest that an approach to assessing the carcinogenicity of 
PAH mixtures employing RPFs of individual PAHs has some potential areas of concern.  We found DBC 
and PAH mixtures containing coal tar to have potency as skin carcinogens much greater than would be 
predicted from the RPFs.  A common biomarker to predict carcinogenicity, covalent DNA adducts, did 
not predict final tumor response.  An RPF approach to risk assessment also assumes (as with TEQs) for 
dioxins/dibenzofurans  (Gies et al., 2007) a common MOA.  Our examination of PAH-dependent 
alterations in the transcriptome from mouse skin calls into question whether or not a common MOA can 
be assumed.  The pattern with DBC was markedly different than BaP and the coal tar-containing mixtures 
were distinct when compared to either BaP or DBC.  Of course, an important caveat to this conclusion is 
that we sampled a single time-point of 12 hours. The pathways in the Figure 1, in addition to the well 
studied Cyp driven diol epoxides,  include peroxidase formation of radical cations and AKR formation of 
o-quinones.  Further studies looking at the role of these additional pathways as mechanisms of DBC 
bioactivation and inhibition of Cyps should be done to broaden our understanding of the complexities and 
differences among different PAHs and mixtures of PAHs. Further study is needed to determine how the 
distinct gene clustering in mouse skin at this time point relates to the tumor response in this 25-week two 
stage initiation-promotion model. 
 
Funding 
15 
 
This work was supported by the National Institute of Environmental Health (grants P42ES016465 and 
P42ES016465-S1). Work at King’s College London is supported by Cancer Research UK. 
 
Acknowledgements 
We would like to thank Dr. Margaret Pratt of US EPA, IRIS/NCEA/ORD, Washington D.C., Dr. Kim 
Anderson’s lab and Glen Wilson in particular, Erin Madeen, Anna Sherman, and Brady Do, Sarah 
Tscheu, Oregon State University,  for their varied technical assistance. Cigarette smoke condensate was a 
generous gift from Hollie Swanson, University of Kentucky. Bradley Stewart carried out the Agilent array 
work at the University of Wisconsin EDGE3 Core Facility.  Volker M. Arlt and David H. Phillips are 
members of ECNIS2 (Environmental Cancer Risk, Nutrition and Individual Susceptibility 2), a European 
Union network of excellence. 
 
Conflict of Interest Statement 
None of the authors of this manuscript have any conflicts of interest associated with this work. 
  
16 
 
References 
 
Allan, S.E., Smith, B.W., Anderson, K.A., 2012. Impact of the deepwater horizon oil spill on bioavailable 
polycyclic aromatic hydrocarbons in gulf of Mexico coastal waters. Environ. Sci. Technol. 46, 
2033-2039. 
Andrysik, Z., Vondracek, J., Marvanova, S., Ciganek, M., Neca, J., Pencikova, K., Mahadevan, B., 
Topinka, J., Baird, W.M., Kozubik, A., Machala, M., 2011. Activation of the aryl hydrocarbon 
receptor is the major toxic mode of action of an organic extract of a reference urban dust 
particulate matter mixture: the role of polycyclic aromatic hydrocarbons. Mutat. Res. 714, 53-62. 
Arif, J.M., Smith, W.A., Gupta, R.C., 1999. DNA adduct formation and persistence in rat tissues 
following exposure to the mammary carcinogen dibenzo[a,l]pyrene. Carcinogenesis 20, 1147-
1150. 
Arlt, V.M., Stiborova, M., Henderson, C.J., Thiemann, M., Frei, E., Aimova, D., Singh, R., Gamboa da 
Costa, G., Schmitz, O.J., Farmer, P.B., Wolf, C.R., Phillips, D.H., 2008. Metabolic activation of 
benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: 
experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29, 656-665. 
ATSDR, 2011. Priority list of hazardous substances.[ http://www.atsdr.cdc.gov/SPL/resources/] 
Baird, W.M., Hooven, L.A., Mahadevan, B., 2005. Carcinogenic polycyclic aromatic hydrocarbon-DNA 
adducts and mechanism of action. Environ. Mol. Mutagen. 45, 106-114. 
Baird, W.M., Mahadevan, B., 2004. The uses of carcinogen-DNA adduct measurement in establishing 
mechanisms of mutagenesis and in chemoprevention. Mutat. Res. 547, 1-4. 
Boffetta, P., Jourenkova, N., Gustavsson, P., 1997. Cancer risk from occupational and environmental 
exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8, 444-472. 
Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P., 2003. A comparison of normalization methods for 
high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193. 
Braithwaite, E., Wu, X., Wang, Z. 1999. Repair of DNA lesions: mechanisms and relative repair 
efficiencies. Mutat. Res. 424,207-219. 
Buters, J.T.M., Mahadevan, B., Quintanilla-Martinez, L., Gonzalez, F.J., Greim, H., Baird, W.M., Luch, 
A., 2002. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor 
formation. Chem Res. Toxicol. 15, 1127-1135. 
Castro, D.J., Baird, W.M., Pereira, C.B., Giovanini, J., Lohr, C.V., Fischer, K.A., Yu, Z., Gonzalez, F.J., 
Krueger, S.K., Williams, D.E., 2008a. Fetal mouse Cyp1b1 and transplacental carcinogenesis 
from maternal exposure to dibenzo(a,l)pyrene. Cancer Prev. Res. 1, 128-134. 
Castro, D.J., Lohr, C.V., Fischer, K.A., Pereira, C.B., Williams, D.E., 2008b. Lymphoma and lung cancer 
in offspring born to pregnant mice dosed with dibenzo[a,l]pyrene: the importance of in utero vs. 
lactational exposure. Toxicol. Appl. Pharmacol. 233, 454-458. 
Cavalieri, E.L., Higginbotham, S., RamaKrishna, N.V., Devanesan, P.D., Todorovic, R., Rogan, E.G., 
Salmasi, S., 1991. Comparative dose-response tumorigenicity studies of dibenzo[alpha,l]pyrene 
versus 7,12-dimethylbenz[alpha]anthracene, benzo[alpha]pyrene and two dibenzo[alpha,l]pyrene 
dihydrodiols in mouse skin and rat mammary gland. Carcinogenesis 12, 1939-1944. 
Cavalieri, E.L., Rogan, E.G., 1992. The approach to understanding aromatic hydrocarbon carcinogenesis. 
The central role of radical cations in metabolic activation. Pharmacol. Ther. 55, 183-194. 
Cavelieri, E.L. Rogan, E.G., 1995. Central role of radical cations in metabolic activation of polycyclic 
aromatic hydrocarbons. Xenobiotica 25, 677-688. 
Chen, K.M., Zhang, S.M., Aliaga, C., Sun, Y.W., Cooper, T., Gowdahalli, K., Zhu, J., Amin, S., El-
Bayoumy, K., 2012. Induction of ovarian cancer and DNA adducts by dibenzo[a,l]pyrene in the 
mouse. Chem. Res. Toxicol. 25, 374-380. 
Cogliano, V.J., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., 
Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., Wild, C.P., 2011. Preventable 
exposures associated with human cancers. J Natl Cancer Inst. 103, 1827-1839. 
17 
 
Courter, L.A., Musafia-Jeknic, T., Fisher, K., Bildfell, R., Giovanini, J., Pereira, C., Baird, W. 2006. 
Urban dust particulate matter alters PAH-induced carcinogenesis by inhibition of CYP1A1 and 
CYP1B1. Tox. Sci. 95:63-73. 
Courter, L.A., Luch, A., Musafia-Jeknic, T., Arlt, V.M., Fischer, K., Bildfell, R., Pereira, C., Phillips, 
D.H., Poirier, M.C., Baird, W.M., 2008. The influence of diesel exhaust on polycyclic aromatic 
hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo. 
Cancer Lett. 265, 135-147. 
Darwiche, N., Ryscavage, A., Perez-Lorenzo, R., Wright, L., Bae, D.S., Hennings, H., Yuspa, S.H., 
Glick, A.B., 2007. Expression profile of skin papillomas with high cancer risk displays a unique 
genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant 
conversion. Oncogene 26, 6885-6895. 
Ding, J., Zhong, J., Yang, Y., Li, B., Shen, G., Su, Y., Wang, C., Li, W., Shen, H., Wang, B., Wang, R., 
Huang, Y., Zhang, Y., Cao, H., Zhu, Y., Simonich, S.L., Tao, S., 2011. Occurrence and exposure 
to polycyclic aromatic hydrocarbons and their derivatives in a rural Chinese home through 
biomass fuelled cooking. Environ. Pollut.  [Epub, doi:10.1016/j.envpol.2011.10.008]. 
Dreij, K., Seidel, A., Jernström, B. 2005. Differential removal of DNA adducts derived from anti-diol 
epoxides of dibenzo[a,l]pyrene and benzo[a]pyrene in human cells. Chem. Res. Toxicol. 18,655-
664. 
Geacintov, N.E., Broyde, S., Buterin, T., Naegeli,H., Wu,M.,Yan, S., Patel, D.J. 2002. Thermodynamic 
and structural factors in the removal of bulky DNA adducts by the nucleotide excision repair 
machinery. Biopolymers 65, 202-210. 
Gies, A., Neumeier, G., Rappolder, M., Konietzka, R., 2007. Risk assessment of dioxins and dioxin-like 
PCBs in food--comments by the German Federal Environmental Agency. Chemosphere 67, 344-
349. 
Glick, A., Ryscavage, A., Perez-Lorenzo, R., Hennings, H., Yuspa, S., Darwiche, N., 2007. The high-risk 
benign tumor: evidence from the two-stage skin cancer model and relevance for human cancer. 
Mol. Carcinog. 46, 605-610. 
Guttenplan, J.B., Kosinska, W., Zhao, Z.L., Chen, K.M., Aliaga, C., Deltondo, J., Cooper, T., Sun, Y.W., 
Zhang, S.M., Jiang, K., Bruggeman, R., Sharma, A.K., Amin, S., Ahn, K., El-Bayoumy, K., 
2011. Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a 
potential new model for oral cancer. Int. J. Cancer 130, 2783-2790. 
Hennings, H., Glick, A.B., Lowry, D.T., Krsmanovic, L.S., Sly, L.M., Yuspa, S.H., 1993. FVB/N mice: 
an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. 
Carcinogenesis 14, 2353-2358. 
Higginbotham, S., RamaKrishna, N.V., Johansson, S.L., Rogan, E.G., Cavalieri, E.L., 1993. Tumor-
initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-
dimethylbenz[a]anthracene and benzo[a]pyrene at low doses in mouse skin. Carcinogenesis 14, 
875-878. 
Huang da, W., Sherman, B.T., Lempicki, R.A., 2009. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57. 
IARC, 2010. Some non-heterocyclic polycyclicaromatic hydrocarbons and some related exposures. 
Monographs on the evaluation of carcinogenic risks to humans Lyon, France. 
[http://monographs.iarc.fr/ENG/Monographs/vol92/mono92.pdf]. 
Kumar, M., Sharma, V.L., Sehgal, A., Jain, M., 2012. Protective effects of green and white tea against 
benzo(a)pyrene induced oxidative stress and DNA damage in murine model. Nutr. Cancer 64, 
300-306. 
Lagerqvist, A., Håkansson, D., Lundin, C., Prochazka, G., Dreij, K., Segerbäck, D., Jerström, B., 
Törnqvist, M., Frank, H., Seidel, A., Erixon, K., Jenssen, D. 2011. DNA repair and replication 
influence the number of mutations per adduct of polycyclic aromatic hydrocarbons in mammalian 
cells. DNA Repair 10,877-886. 
18 
 
LaVoie, E.J., He, Z.M., Meegalla, R.L., Weyand, E.H., 1993. Exceptional tumor-initiating activity of 4-
fluorobenzo[j]-fluoranthene on mouse skin: comparison with benzo[j]-fluoranthene, 10-fluoro-
benzo[j]fluoranthene, benzo[a]pyrene, dibenzo[a,l]pyrene and 7,12-dimethylbenz[a]anthracene. 
Cancer Lett. 70, 7-14. 
Lewtas, J., 2007. Air pollution combustion emissions: characterization of causative agents and 
mechanisms associated with cancer, reproductive, and cardiovascular effects. Mutat. Res. 636, 
95-133. 
Lijinsky, W., 1991. The formation and occurrence of polynuclear aromatic hydrocarbons associated with 
food. Mutat. Res. 259, 251-261. 
Lomas, A., Leonardi-Bee, J., Bath-Hextall, F., 2012. A systematic review of worldwide incidence of non-
melanoma skin cancer. Br J Dermatol. 166, 1069-1080. 
Mahadevan, B., Luch, A., Atkin, J., Haynes, M., Nguyen, T., Baird, W.M., 2007a. Inhibition of human 
cytochrome p450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in 
culture. J. Biochem. Mol. Toxicol. 21, 101-109. 
Mahadevan, B., Marston, C.P., Dashwood, W.M., Li, Y., Pereira, C., Baird, W.M., 2005. Effect of a 
standardized complex mixture derived from coal tar on the metabolic activation of carcinogenic 
polycyclic aromatic hydrocarbons in human cells in culture. Chem. Res. Toxicol. 18, 224-231. 
Mahadevan, B., Marston, C.P., Luch, A., Dashwood, W.M., Brooks, E., Pereira, C., Doehmer, J., Baird, 
W.M., 2007b. Competitive inhibition of carcinogen-activating CYP1A1 and CYP1B1 enzymes 
by a standardized complex mixture of PAH extracted from coal tar. Int. J. Cancer 120, 1161-
1168. 
Mao, I.F., Chen, C.-N., Lin, Y.-C., Chen, M.-L., 2007. Airborne particle PM2.5/PM10 mass distribution 
and particle-bound PAH concentrations near a medical waste incinerator. Atmos. Environ. 41, 
2467-2475. 
Marczynski, B., Pesch, B., Wilhelm, M., Rossbach, B., Preuss, R., Hahn, J.U., Rabstein, S., Raulf-
Heimsoth, M., Seidel, A., Rihs, H.P., Adams, A., Scherenberg, M., Erkes, A., Engelhardt, B., 
Straif, K., Kafferlein, H.U., Angerer, J., Bruning, T., 2009. Occupational exposure to polycyclic 
aromatic hydrocarbons and DNA damage by industry: a nationwide study in Germany. Arch. 
Toxicol. 83, 947-957. 
Marston, C.P., Pereira, C., Ferguson, J., Fischer, K., Hedstrom, O., Dashwood, W.M., Baird, W.M., 2001. 
Effect of a complex environmental mixture from coal tar containing polycyclic aromatic 
hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of 
carcinogenic PAH in mouse epidermis. Carcinogenesis 22, 1077-1086. 
Nesnow, S., Mass, M.J., Ross, J.A., Galati, A.J., Lambert, G.R., Gennings, C., Carter, W.H., Jr., Stoner, 
G.D., 1998. Lung tumorigenic interactions in strain A/J mice of five environmental polycyclic 
aromatic hydrocarbons. Environ. Health Perspect. 106 Suppl 6, 1337-1346. 
Niestroy, J., Barbara, A., Herbst, K., Rode, S., van Liempt, M., Roos, P.H., 2011. Single and concerted 
effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon 
carcinoma cell line Caco-2. Toxicol. In Vitro 25, 671-683. 
Palackal, N.T., Burczynski, M.E., Harvey, R.G., Penning, T.M., 2001. The ubiquitous aldehyde reductase 
(AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in 
polycyclic aromatic hydrocarbon activation. Biochemistry 40, 10901-10910. 
Palackal, N.T., Lee, S.H., Harvey, R.G., Blair, I.A., Penning, T.M., 2002. Activation of polycyclic 
aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase 
(AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J. 
Biol. Chem. 277, 24799-24808. 
Penning, T.M., Ohnishi, S.T., Ohnishi, T., Harvey, R.G., 1996. Generation of reactive oxygen species 
during the enzymatic oxidation of polycyclic aromatic hydrocarbon trans-dihydrodiols catalyzed 
by dihydrodiol dehydrogenase. Chem. Res. Toxicol. 9, 84-92. 
Phillips, D.H., Arlt, V.M., 2007. The 32P-postlabeling assay for DNA adducts. Nat. Protoc. 2, 2772-2781. 
19 
 
Phillips, D.H., Castegnaro, M., 1999. Standardization and validation of DNA adduct postlabelling 
methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 
14, 301-315. 
Poster, D.L., Alda, M.J.L.D., Wise, S.A., Chuang, J.C., Mumford, J.L., 2000. Determination of PAHs in 
combustion-related samples and in SRM 1597, complex mixture of PAHs from coal tar. Polycycl. 
Aromat. Compd. 20, 79-95. 
Shah, A.R., Singhal, M., Klicker, K.R., Stephan, E.G., Wiley, H.S., Waters, K.M., 2007. Enabling high-
throughput data management for systems biology: the Bioinformatics Resource Manager. 
Bioinformatics 23, 906-909. 
Shimada, T., 2006. Xenobiotic-metabolizing enzymes involved in activation and detoxification of 
carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet. 21, 257-276. 
Shorey, L.E., Castro, D.J., Baird, W.M., Siddens, L.K., Lohr, C.V., Matzke, M.M., Waters, K.M., Corley, 
R.A., Williams, D.E., 2012. Transplacental carcinogenesis with dibenzo[def,p]chrysene (DBC): 
timing of maternal exposures determines target tissue response in offspring. Cancer Lett. 317, 49-
55. 
Shou, M., Krausz, K.W., Gonzalez, F.J., Gelboin, H.V., 1996. Metabolic activation of the potent 
carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver 
microsomes. Carcinogenesis 17, 2429-2433. 
Slaga, T.J., Das, S.B., Rice, J.M., Thompson, S., 1974. Fractionation of mouse epidermal chromatin 
components. J. Invest. Dermatol. 63, 343-349. 
Tang, D., Phillips, D.H., Stampfer, M., Mooney, L.A., Hsu, Y., Cho, S., Tsai, W.Y., Ma, J., Cole, K.J., 
She, M.N., Perera, F.P., 2001. Association between carcinogen-DNA adducts in white blood cells 
and lung cancer risk in the physicians health study. Cancer Res. 61, 6708-6712. 
U.S. EPA. Development of a Relative Potency Factor (RPF) Approach for Polycyclic Aromatic 
Hydrocarbon (PAH) Mixtures (External Review Draft). U.S. EPA, Washington, DC, EPA/635/R-
08/012A, 2010. 
 
Uno, S., Dalton, T.P., Dragin, N., Curran, C.P., Derkenne, S., Miller, M.L., Shertzer, H.G., Gonzalez, 
F.J., Nebert, D.W., 2006. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 
important in detoxication, CYP1B1 metabolism required for immune damage independent of 
total-body burden and clearance rate. Mol. Pharmacol. 69, 1103-1114. 
Weissenfels, W.D., Klewer, H.J., Langhoff, J., 1992. Adsorption of polycyclic aromatic hydrocarbons 
(PAHs) by soil particles: influence on biodegradability and biotoxicity. Appl. Microbiol. 
Biotechnol. 36, 689-696. 
Wester, P.W., Muller, J.J., Slob, W., Mohn, G.R., Dortant, P.M., Kroese, E.D., 2011. Carcinogenic 
activity of benzo[a]pyrene in a 2 year oral study in Wistar rats. Food Chem. Toxicol. 50, 927-935. 
Wickramasinghe, A.P., Karunaratne, D.G., Sivakanesan, R., 2012. PM(10)-bound polycyclic aromatic 
hydrocarbons: Biological indicators, lung cancer risk of realistic receptors and 'source-exposure-
effect relationship' under different source scenarios. Chemosphere 87, 1381-1387. 
Wu, M., Yan, S., Patel, D.J., Geacintov, N.E., Broyde, S., 2002. Relating repair susceptibility of 
carcinogen-damaged DNA with structural distortion and thermodynamic stability. Nucleic Acids 
Res. 30:3422-3432. 
Xue, W., Warshawsky, D., 2005. Metabolic activation of polycyclic and heterocyclic aromatic 
hydrocarbons and DNA damage: a review. Toxicol. Appl. Pharmacol. 206, 73-93. 
Yu, Z., Loehr, C., Fischer, K.A., Louderback, M., Krueger, S.K., Dashwood, R.H., Kerkvliet, 
N.I., Pereira, C.B., Jennings-Gee, J., Dance, S.T., Miller, M.S., Bailey, G.S. and 
Williams, D.E., 2006.  In utero exposure of mice to dibenzo[a,l]pyrene produces 
lymphoma in the offspring: role of the aryl hydrocarbon receptor.  Cancer Res. 66, 755-
762. 
 
20 
 
Yu, Z., Mahadevan, B., Lohr, C.V., Fischer, K.A., Louderback, M.A., Krueger, S.K., Pereira, C.B., 
Albershardt, D.J., Baird, W.M., Bailey, G.S., Williams, D.E., 2006. Indole-3-carbinol in the 
maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the 
polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene. Carcinogenesis 27, 2116-2123. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
TABLE AND FIGURE LEGENDS 
 
Fig. 1.  Metabolic pathways for bioactivation of PAHs using the fjord containing dibenzo[def,p]chrysene 
as an example. From left to right, the peroxidase pathway resulting in radical cations which may be 
capable of forming DNA adducts. The most well characterized P450 CYP dependent epoxygenation 
hydrolysis by epoxide hydrolase shows one of two (+) and (-) trans- DBC-11,12 DHD products followed 
by epoxygenation to one of four DBCDE products capable of adducting to macromolecules such as DNA. 
Also shown is the AKR pathway producing semi-quinones and quinones. *These reversible reactions can 
produce radical oxygen species resulting in additional oxidative stress.  
 
Fig.2. Kaplan-Meier estimation of percent tumor bearing animals throughout 25 wk of promotion with 
TPA (6.5 nmol/200 µl), twice weekly starting two weeks post initiation. Initiation doses were 200 µl 
toluene (Ctrl), 400 nmol (100 µg) BaP, 4 nmol (1.2 µg) DBC, 1 mg DPE (mix 1), 1 mg DPE + 1 mg CTE 
(mix 2), and 1 mg DPE + 1 mg CTE + 2 mg CSC (mix 3). Individuals that died tumor free before the end 
of 25 weeks and those that were tumor free at the end of 25 weeks were censored and are indicated by an 
*.  
 
Fig. 3. Tumor multiplicity in tumor-bearing animals (TBA, female FVB/N mice) with at least one tumor 
after initiation with a carcinogen followed by 25 wk of promotion with TPA.  Dots represent individual 
animals with at least one tumor at the end of promotion; mean numbers of tumors in a given treatment 
represented by line.  The number of mice surviving to 10 months in each group from the initial 35 is 
indicated below the treatments. 
 
Fig. 4. Proportional incidence of hyperplasia, dysplasia, papillomas, carcinoma in situ (CIS), and 
squamous cell carcinoma (SCC) in each treatment group, determined by histopathology as described in 
Materials and Methods.  
 
Fig. 5 Histopathology of epidermal hyperplasia, squamous papilloma and squamous cell carcinoma of the 
skin. 
A. Low (left) and high (right) magnification of skin with epidermal hyperplasia. In the low 
magnification, normal thickness of the epidermis is shown on the left (arrow head) and increased 
thickness of the hyperplastic epidermis on the right (arrow). While the number of cell layers is 
increased, keratinocytes progress in the same orderly manner from basal cells (arrow head) at 
bottom to fully keratinized cells (arrow) at top as they do in normal epidermis.  
B. Low (left) and high (right) magnification of skin with squamous papilloma. At lower 
magnification, the small, protruding mass is bordered by epidermis of normal (left) to slightly 
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increased thickness (right). It comprises a fibrovascular core (asterisk) covered with very thick 
epithelium that, at high magnification, recapitulates orderly keratinization of basal cells (arrow 
head) to fully keratinized cells (arrow) of normal and hyperplastic epidermis shown in A.  
C. Low (left) and high (right) magnification of skin with squamous cell carcinoma. At low 
magnification, the plaque-like mass has a flat to umbilicated top (asterisk) and deeply infiltrates 
into the subcutis (arrow heads). At higher magnification, keratinocytes are arranged in solid nests. 
Individual keratinocytes (arrow) and groups of keratinocytes (arrow heads) haphazardly 
keratinize without orderly progression. A concentrically layered keratin pearl is present at the 
upper right (asterisk in center). Note that high magnification is not the same as in A and B.  
 
 
Fig. 6. DNA adduct formation in FVB mouse skin tissue 12 h post-treatment with 200 µl toluene (Ctrl), 
400 nmol (100 µg) BaP, 4 nmol (1.2 µg) DBC, 1 mg DPE (mix 1), 1 mg DPE +  1 mg CTE (mix 2), or 1 
mg DPE + 1 mg CTE + 2 mg CSC (mix 3). DNAadducts were measured by the nuclease P1 enrichment 
version of 32P-postlabeling method. (A) Bars represent mean ± SD, N=5 pools, 2 mice/pool. Total adducts 
were measured across the DRZ, diagonal radioactive zone of the TLC autoradiogram. (B) Representative 
autoradiograms showing DNA adduct profiles. 
 
Fig. 7.  Principal components analysis of gene expression data by treatment.  Each data point represents a 
biological replicate (N=4 per treatment).  All genes differentially regulated (p<0.05) between treated and 
toluene control were included in analysis.  Replicates cluster based on treatment group.  Toluene control 
= pink; Mix 1 = brown; Mix 2 = gray; Mix 3 = green; B[a]P = red; DBC = blue. 
 
Fig. 8.  Comparison of differentially expressed genes among PAH mixture treatments by Venn diagram 
(A). Values represent genes significant (p<0.05) versus toluene control.  Genes common between mix 2 
and mix 3, but unique from mix 1 are shown as a heatmap (B).  Values in heatmap are fold-change (Log2) 
compared to toluene control (red is up regulated, green is down regulated and black is no change).  GO 
biological processes significantly enriched (p<0.05) for up or down regulated genes are shown.  
 
Fig. 9.   Gene expression of select xenobiotic metabolizing enzymes, including Phase 1 CYP enzymes 
and Phase 2 enzymes, regulated by PAH mixtures 2 and 3.  Values are average Log2 fold-change (± SE) 
for each treatment group (N=4 biological replicates) measured by Agilent microarray.  *Indicates p<0.05 
compared to toluene control. 
 
 
 
